Oluwatomi L Ladipo1, Yi Ren2, Keenan B Caddell1, Anuyuga Sampathkumar1, Chandra A Almond1, Oluwadamilola M Fayanju3. 1. Department of Surgery, Duke University Medical Center, Box 3513, Durham, NC, 27710, USA. 2. Biostatistics Shared Resource, Duke Cancer Institute, Durham, NC, 27710, USA. 3. Department of Surgery, Duke University Medical Center, Box 3513, Durham, NC, 27710, USA; Women's Cancer Program, Duke Cancer Institute, Durham, NC, 27710, USA; Department of Population Health Sciences, Duke University School of Medicine, 215 Morris Street, Durham, NC, 27701, USA; Duke Forge, Duke University, Durham, NC, 27710, USA; Department of Surgery, Durham VA Medical Center, 508 Fulton St, Durham, NC, 27705, USA. Electronic address: lola.fayanju@duke.edu.
Abstract
INTRODUCTION: We compared characteristics and outcomes by treatment sequence among patients with metaplastic breast cancer (MBC), an aggressive subtype. METHODS: Women ≥18 years old with newly diagnosed Stage I-III MBC from 2003 to 2018 who received any treatment in our health system were identified. Unadjusted overall survival (OS) was estimated with the Kaplan-Meier method; the log-rank test was used to compare survival differences between recipients of neoadjuvant (NACT) and adjuvant chemotherapy (ACT). RESULTS: Of the 91 MBC patients identified, 60 received chemotherapy. NACT recipients (n = 20, median age 46.5 y) were younger than ACT recipients (n = 40, median age 60.5 y, p < 0.001) but similar with regards to race and radiation receipt. There was no significant OS difference between NACT and ACT recipients (log-rank p = 0.15), which remained true when patients were stratified by age (≥50 y vs < 50 y). CONCLUSIONS: Among MBC patients, NACT recipients were younger than ACT recipients, but there was no survival difference by treatment sequence.
INTRODUCTION: We compared characteristics and outcomes by treatment sequence among patients with metaplastic breast cancer (MBC), an aggressive subtype. METHODS: Women ≥18 years old with newly diagnosed Stage I-III MBC from 2003 to 2018 who received any treatment in our health system were identified. Unadjusted overall survival (OS) was estimated with the Kaplan-Meier method; the log-rank test was used to compare survival differences between recipients of neoadjuvant (NACT) and adjuvant chemotherapy (ACT). RESULTS: Of the 91 MBC patients identified, 60 received chemotherapy. NACT recipients (n = 20, median age 46.5 y) were younger than ACT recipients (n = 40, median age 60.5 y, p < 0.001) but similar with regards to race and radiation receipt. There was no significant OS difference between NACT and ACT recipients (log-rank p = 0.15), which remained true when patients were stratified by age (≥50 y vs < 50 y). CONCLUSIONS: Among MBC patients, NACT recipients were younger than ACT recipients, but there was no survival difference by treatment sequence.
Authors: Cecilia T Ong; Brittany M Campbell; Samantha M Thomas; Rachel A Greenup; Jennifer K Plichta; Laura H Rosenberger; Jeremy Force; Allison Hall; Terry Hyslop; E Shelley Hwang; Oluwadamilola M Fayanju Journal: Ann Surg Oncol Date: 2018-05-31 Impact factor: 5.344
Authors: Zahraa Al-Hilli; Grace Choong; Michael G Keeney; Daniel W Visscher; James N Ingle; Matthew P Goetz; James W Jakub Journal: Breast Cancer Res Treat Date: 2019-05-22 Impact factor: 4.872
Authors: Patricia Cortazar; Lijun Zhang; Michael Untch; Keyur Mehta; Joseph P Costantino; Norman Wolmark; Hervé Bonnefoi; David Cameron; Luca Gianni; Pinuccia Valagussa; Sandra M Swain; Tatiana Prowell; Sibylle Loibl; D Lawrence Wickerham; Jan Bogaerts; Jose Baselga; Charles Perou; Gideon Blumenthal; Jens Blohmer; Eleftherios P Mamounas; Jonas Bergh; Vladimir Semiglazov; Robert Justice; Holger Eidtmann; Soonmyung Paik; Martine Piccart; Rajeshwari Sridhara; Peter A Fasching; Leen Slaets; Shenghui Tang; Bernd Gerber; Charles E Geyer; Richard Pazdur; Nina Ditsch; Priya Rastogi; Wolfgang Eiermann; Gunter von Minckwitz Journal: Lancet Date: 2014-02-14 Impact factor: 79.321
Authors: Oluwadamilola M Fayanju; Yi Ren; Samantha M Thomas; Rachel A Greenup; Jennifer K Plichta; Laura H Rosenberger; Nina Tamirisa; Jeremy Force; Judy C Boughey; Terry Hyslop; E Shelley Hwang Journal: Ann Surg Date: 2018-10 Impact factor: 12.969
Authors: Reva K Basho; Michael Gilcrease; Rashmi K Murthy; Thorunn Helgason; Daniel D Karp; Funda Meric-Bernstam; Kenneth R Hess; Shelley M Herbrich; Vicente Valero; Constance Albarracin; Jennifer K Litton; Mariana Chavez-MacGregor; Nuhad K Ibrahim; James L Murray; Kimberly B Koenig; David Hong; Vivek Subbiah; Razelle Kurzrock; Filip Janku; Stacy L Moulder Journal: JAMA Oncol Date: 2017-04-01 Impact factor: 31.777